Skip to content

The Clinical and Pharmacoeconomic Impact of Rapid Diagnostic Test (Multiplex PCR FilmArray) on Antimicrobial Decision Making Compared to Conventional Decision Making Among Critically Ill Patients

The Clinical and Pharmacoeconomic Impact of Rapid Diagnostic Test (Multiplex PCR FilmArray) on Antimicrobial Decision Making Compared to Conventional Decision Making Among Critically Ill Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05759494
Enrollment
100
Registered
2023-03-08
Start date
2023-05-01
Completion date
2024-02-01
Last updated
2023-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

We will show in this study the impact of use the rapid diagnostic method (multiplex PCR filmArray) on clinical and pharmacoeconomic aspects among Critically Ill Patients.

Detailed description

Prospective and retrospective study on 100 patients complaining from sepsis in intensive care unit in International Medical center. Two phase study 50 patients before and 50 patients after use rapid diagnostic test (multiplex PCR filmArray)

Interventions

DIAGNOSTIC_TESTrapid diagnostic test (multiplex PCR filmArray)

novel diagnostic platform, the FilmArray®, which combines automated sample preparation, nucleic acid extraction and PCR-based detection of 31 separate targets from a single unprocessed sample in one hour. It combines nesting and multiplexing of the PCR (referred to here as nested multiplex or nmPCR) together with DNA melting curve analysis.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
16 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age between 18 and 85 years * Critically ill patients admitted to ICU, diagnosed as sepsis.

Exclusion criteria

* Surviving time less than 48 hours.

Design outcomes

Primary

MeasureTime frameDescription
clinicalthrough study completion, an average of 1 yearClinical resolution of sepsis ( by percentage)
Pharmacoeconomicthrough study completion, an average of 1 year1-Reduction of cost and reduction of respective antimicrobial cases (by percentage )
pharmacoeconomicthrough study completion, an average of 1 yearDOT of antimicrobial (by days )

Contacts

Primary ContactRAED EMAD ALY, MASTER
raedemad89@gmail.com00201111871351
Backup Contactmohamed amin fakher, M.D
mohamed.fakher@kasralainy.ed.eg00201062275876

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026